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Background: The p38 mitogen-activated protein kinases (MAPK) family plays pivotal roles in skeletal muscle
metabolism. Recent evidence revealed that p38α and p38β exert paradoxical effects on muscle protein
homeostasis. However, it is unknown why p38β, but not p38α, is capable of mediating muscle catabolism via
selective activation of the C/EBPβ that upregulates atrogin1/MAFbx.
Methods: Tryptic phosphopeptide mapping was carried out to identify p38α- and p38β-mediated phosphorylation
sites in C/EBPβ. Chromosome immunoprecipitation (ChIP) assay was used to evaluate p38α and p38β effect on
C/EBPβ binding to the atrogin1/MAFbx promoter. Overexpression or siRNA-mediated gene knockdown of p38α and
p38β, and site-directed mutagenesis or knockout of C/EBPβ, were used to analyze the roles of these kinases in
muscle catabolism in C2C12 myotubes and mice.
Results: Cellular expression of constitutively active p38α or p38β resulted in phosphorylation of C/EBPβ at multiple
serine and threonine residues; however, only p38β phosphorylated Thr-188, which had been known to be critical to
the DNA-binding activity of C/EBPβ. Only p38β, but not p38α, activated C/EBPβ-binding to the atrogin1/MAFbx
promoter. A C/EBPβ mutant in which Thr-188 was replaced by alanine acted as a dominant-negative inhibitor of
atrogin1/MAFbx upregulation induced by either p38β or Lewis lung carcinoma (LLC) cell-conditioned medium
(LCM). In addition, knockdown of p38β specifically inhibited C/EBPβ activation and atrogin1/MAFbx upregulation
induced by LCM. Finally, expression of active p38β in mouse tibialis anterior specifically induced C/EBPβ
phosphorylation at Thr-188, atrogin1/MAFbx upregulation and muscle mass loss, which were blocked in
C/EBPβ-null mice.
Conclusions: The α and β isoforms of p38 MAPK are capable of recognizing distinct phosphorylation sites in a
substrate. The unique capacity of p38β in mediating muscle catabolism is due to its capability in phosphorylating
Thr-188 of C/EBPβ.
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The p38 mitogen-activated protein kinases (MAPK)
family plays a pivotal role in skeletal muscle by mediat-
ing diverse cellular activities, and interestingly, some of
which result in paradoxical effects. For example, p38
mediates both insulin stimulation of glucose uptake [1]
and TNF-α stimulation of insulin resistance [2] in
muscle. In the context of skeletal muscle protein homeo-
stasis, p38 responds to both catabolic (lipopolysacchar-
ide, cytokines, and ROS) [3-5] and anabolic (insulin and* Correspondence: yi-ping.li@uth.tmc.edu
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reproduction in any medium, provided the orexercise) stimuli [6]. On one hand, p38 stimulates
muscle satellite cell proliferation [7] and differentiation
[8], which increases muscle mass; on the other hand,
p38 stimulates muscle protein degradation leading to
muscle atrophy [3-5]. Intriguingly, p38 has the capacity
to activate different protein substrates depending on the
cellular environment [7]. It is of great interest to under-
stand how the p38 MAPK family is able to mediate the
discrete and sometimes opposing effects in response to
diverse physiological and pathological stimuli. The fam-
ily of MAPK is composed of at least four members (α, β,
γ and δ), which enable the transduction of a variety
of extracellular signals into distinct nuclear responsesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhang and Li Skeletal Muscle 2012, 2:20 Page 2 of 9
http://www.skeletalmusclejournal.com/content/2/1/20[9-11]. The α, β, and γ isoforms are found in muscle
cells. Recently, it became clear that p38α MAPK plays
an essential role in myogenic differentiation [12,13].
On the other hand, p38γ MAPK appears to regulate
the expansion of myogenic precursor cells [14], endur-
ance exercise-induced mitochondrial biogenesis and
angiogenesis [15], as well as glucose uptake [16]. But,
little was known about the function of p38β until our
most recent discovery of its role in regulating the
atrogin1/MAFbx gene [17].
Cachexia, a wasting disease characterized by loss of
muscle mass with or without loss of fat mass, is frequently
associated with such diseases as cancer, sepsis, AIDS, con-
gestive heart failure, diabetes, chronic renal failure and
chronic obstructive pulmonary disease (COPD). Cachexia
is distinct from starvation-, disuse-, aging-, primary de-
pression-, malabsorption- and hyperthyroidism-induced
muscle mass loss and is associated with increased morbid-
ity and mortality [18,19]. The prominent clinical feature of
cachexia is weight loss with anorexia, inflammation, in-
sulin resistance, and increased muscle protein break-
down. Increased muscle protein breakdown in cachexia
is at least partially due to accelerated muscle proteoly-
sis by the ubiquitin-proteasome pathway, a common
pathway of muscle mass loss due to pathological as
well as physiological causes [20]. However, the signal-
ing mechanism of the activation of the ubiquitin-
proteasome pathway in cachexia appears to be different
from that of physiological muscle atrophy. It is well
established that a depression in AKT activity activates
FoxO1/3 transcription factors, which upregulates two
key ubiquitin ligases (E3 proteins), atrogin1/MAFbx and
MuRF1, in animal models of physiological muscle atro-
phy caused by fasting, denervation and disuse [21-23].
In animal models of cachexia, however, AKT is often
activated, which leads to the inactivation of FoxO1/3
[4,5,24]. In fact, it has been shown in animal models of
cachexia that upregulation of MuRF1 is mediated by
NF-κB [25], and upregulation of atrogin1/MAFbx is
mediated by p38 MAPK [4,5].
We showed most recently that among the known p38
MAPK isoforms only p38β MAPK is capable of upregu-
lating atrogin1/MAFbx via the activation of transcription
factor C/EBPβ in response to tumor cell-conditioned
medium. In addition, we demonstrated that p38β MAPK
upregulation of atrogin1/MAFbx is independent of the
AKT-FoxO1/3 signaling pathway [17]. Thus, p38β
emerged as a key mediator and a specific therapeutic
target of cachexia. Notwithstanding, why p38β is
uniquely capable of activating C/EBPβ among the p38
isoforms is unknown. The current study is designed to
address the mechanism through which p38β specifically
activates C/EBPβ in the context of tumor-induced cach-
exia. We demonstrate that while p38β shares somecommon phosphorylation sites with p38α, it specifically
phosphorylates the Thr-188 residue of C/EBPβ, which
activates C/EBPβ binding to the atrogin1/MAFbx pro-
moter and upregulates this gene in response to a tumor.
Methods
Tryptic phosphopeptide mapping was carried out to
identify p38α- and p38β-mediated phosphorylation sites
in C/EBPβ. ChIP assay was used to evaluate p38α and
p38β effect on C/EBPβ-binding to the atrogin1/MAFbx
promoter. Overexpression or siRNA-mediated gene
knockdown of p38α and p38β, and site-directed muta-
genesis or knockout of C/EBPβ, were used to analyze
the roles of these kinases in muscle catabolism in C2C12
myotubes and mice.
Tryptic phosphopeptide mapping
HEK293T cells (American Type Culture Collection,
Manassas, VA, USA) cultured in 150 mm culture plates
that were ~50% confluent were co-transfected with a
plasmid encoding LAP with a FLAG tag (Addgene) and
a plasmid encoding constitutively active p38α or p38β
[26] (10 μg each) using deacylated polyethylenimine
(PEI) 22000 [27], a gift from Dr. Guangwei Du (Univer-
sity of Texas Health Science Center at Houston, Hous-
ton, TX, USA). The cell culture medium was replaced
with fresh medium at 24 h. Cells were lysed in RIPA buf-
fer (50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 2 mM
EDTA, 1% NP-40, 0.1% SDS, 2 mM phenylmethylsul-
phonylfluoride (PMSF), 0.5% sodium deoxycholate, 1
mM NaF, 1/100 protease inhibitor cocktail, and 1/100
phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis,
MO, USA) after an additional incubation of 24 h. LAP
in cell lysates was precipitated using FLAG-M2 magnetic
beads (Sigma-Aldrich) and subjected to 10% SDS-PAGE.
The gel was then stained with Coommassie Blue R-250.
The LAP band was cut out and subjected to tryptic
phosphopeptide mapping conducted by Taplin Mass
Spectrometry Facility at Harvard Medical School using
an LTQ-Orbitrap mass spectrometer (Thermo Electron,
West Palm Beach, FL, USA).
Myogenic cell culture and transfection
Murine C2C12 myoblasts (American Type Culture Col-
lection, Manassas, VA, USA) were cultured in growth
medium (DMEM supplemented with 10% fetal bovine
serum) at 37°C under 5% CO2. At approximately 85 to
90% confluence, myoblast differentiation was induced by
incubation for 96 h in differentiation medium (DMEM
supplemented with 4% heat-inactivated horse serum) to
form myotubes. Plasmids encoding constitutively active
p38 isoforms [26] or a C/EBPβ mutant (p3xFlag-CMV-
10-LAP-T188A) were transfected into C2C12 myoblasts
of 50% confluence at 1 μg/well in six-well plates using
Figure 1 Isolation of C/EBPβ phosphorylated by p38α or p38β
MAPK for tryptic phosphopeptide mapping. HEK293T cells were
co-transfected with plasmids encoding C/EBPβ (LAP fused with the
FLAG tag) and constitutively active p38α or p38β (fused with the HA
tag). After 48 h incubation the cells were lysed. Expression of the
transfected plasmids was verified by western blot analysis of HA and
FLAG. Activity of over-expressed p38α and p38β was evaluated by
western blot analysis of ATF2 activation (A). Overexpressed C/EBPβ
was pulled down with FLAG-M2 magnetic beads and separated by
SDS-PAGE. The gel was stained with Coommassie Blue R-250 (B).
The C/EBPβ band was then cut out and analyzed by tryptic
phosphopeptide mapping utilizing mass spectrometry for
phosphorylated amino acid residues. MAPK, mitogen-activated
protein kinase.
Table 1 Expression of constitutively active p38α or p38β
resulted in the phosphorylation of diverse amino acid
residues in C/EBPβ
Kinase Phosphorylated amino acid residues in C/EBPβ
p38α Ser110, Tyr108
p38β Ser182, Ser183, Ser190, Thr188
p38α/p38β Ser64, Ser184, Ser222, Ser276
The C/EBPβ bands cut out from SDS-PAGE described in Figure 1B were
analyzed by tryptic phosphopeptide mapping utilizing mass spectrometry.
Identified phosphorylated amino acid residues in C/EBPβ are listed.
Zhang and Li Skeletal Muscle 2012, 2:20 Page 3 of 9
http://www.skeletalmusclejournal.com/content/2/1/20deacylated polyethylenimine (PEI) 22000. At 24 h we
induced the cells to differentiate by switching them to
differentiation medium. When indicated, myotubes were
treated with Lewis lung carcinoma cell (National Cancer
Institute, Bethesda, MD, USA)-conditioned medium
(LCM, 25% final volume) [17] or directly harvested. Cell
lysate was prepared using the RIPA buffer for further
analyses.
Chromosome immunoprecipitation assay
Chromosome immunoprecipitation (ChIP) assay was
performed as previously described [17].
Generation of expression vector for a C/EBPβ mutant
(LAP-T188A)
A plasmid encoding C/EBPβ in which Thr-188 was
replaced by alanine in the pcDNA3 vector (a gift from
Dr. Qi-Qun Tang of Fudan University, Shanghai, China)
was digested at BamHI and EcoRI restriction sites to re-
lease the cDNA insert. That insert was then subcloned
into the p3xFlag-CMV-10 vector (Sigma-Aldrich) at the
same restriction sites to generate plasmid p3xFlag-
CMV-10-LAP-T188A.
Western blot analysis
Cell and muscle lysate were prepared and western blot
analysis was carried out as described previously [17].
Antibodies for total and/or phosphorylated ATF2,
FoxO1 (Thr-24)/FoxO3a (Thr-32) and C/EBPβ phos-
phorylated at Thr-188 were from Cell Signaling Tech-
nology (Danvers, MA, USA). Antibody for atrogin1/
MAFbx was from ECM Biosciences (Versailles, KY,
USA). Antibodies to C/EBPβ (H-7) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibody to
the HA tag was from Covance (Princeton, NJ, USA).
Data were normalized to GAPDH.
Gene knockdown by siRNA
p38α-specific siRNA (5′-CUCCUUUACUAUCUUUCU
CAA-3′) and p38β-specific siRNA (5′-GUCCUGAGGUU
CUAGCAAAdTdT-3′) were synthesized by Sigma-Aldrich
and transfected into C2C12 myoblasts by electroporation
(5 μg/1 × 107 cells) with the Nucleofector system (Lonza,
Walkersville, MD, USA), according to the manufacturer’s
protocol. Control siRNA was obtained from Ambion
(Austin, TX, USA). Differentiation was induced 24 h after
transfection.
Animal use
Experimental protocols were approved in advance by the
institutional Animal Welfare Committee at the Univer-
sity of Texas Health Science Center at Houston. C/
EBPβ−/− mice in C57BL/6 background were bred from
C/EBPβ−/+ mice generated by Dr. Peter Johnson of NCI[28]. While the mice were under anesthesia, plasmids
encoding constitutively active p38α or p38β were
injected into the tibialis anterior (TA) of the right leg for
each mouse (100 μg in 50 μl), and the empty vector
pcDNA3.1 was injected into the left leg as control. Im-
mediately after plasmid injection, TA was electroporated
by applying square-wave electrical pulses (100 V/cm)
eight times with an electrical pulse generator (Model
830, BTX) at a rate of one pulse per second, with each
pulse being 20 ms in duration, through a pair of stainless
steel needles that were 5 mm apart. The above transfec-
tion procedure was repeated in 7 days. In another 7
days, the mice were sacrificed and TAs were collected
for analysis.
Statistical analysis
Data were analyzed with one-way ANOVA or student t
test using the SigmaStat software (Systat Software, Point
Richmond, CA, USA) as indicated. When applicable,
Figure 2 Expression of constitutively active p38β in C2C12
myotubes resulted in specific phosphorylation of C/EBPβ at
Thr-188 and upregulation of atrogin1/MAFbx. C2C12 myoblasts
were transfected with a plasmid encoding constitutively active p38α,
p38β or the empty vector (control). The myoblasts were allowed to
differentiate for 96 h to form myotubes that were then harvested
and analyzed for ATF2 activation, Thr-188 phosphorylation in C/EBPβ
and level of atrogin1/MAFbx using western blotting.
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normalized to a value of 1 without showing variations
(actual variations were within a normal range). A P value
<0.05 was considered to be statistically significant. Data
are presented as the mean ± S.E.Figure 3 p38β is critical to LCM-induced phosphorylation of C/EBPβ at Th
transfected with siRNA as indicated. After differentiation, myotubes were treated
phosphorylation of C/EBPβ at Thr-188 were evaluated by western blotting (A). In
Optical density of the bands that represent C/EBP phosphorylated at Thr-188 or
control without LCM treatment and †denotes a difference from control with LCResults
p38β MAPK specifically phosphorylates the Thr-188
residue of C/EBPβ
C/EBPβ is a transcription factor that is normally
repressed due to the intrinsic repression of its DNA-
binding and transactivation functions [29,30]. The DNA-
binding function of C/EBPβ is activated by sequential
phosphorylation of specific amino acid residues by mul-
tiple kinases [31-33]. C/EBPβ was previously shown to
be a p38 substrate in vitro [34]. Recently, we showed
that p38 interacts with and phosphorylates C/EBPβ in
C2C12 myotubes. In addition, while the p38α/β inhibitor
SB202190 blocks tumor-induced atrogin1/MAFbx upre-
gulation, only p38β is capable of upregulating atrogin1/
MAFbx via the activation of C/EBPβ [17]. To investigate
why p38β, but not p38α, has the capacity for activating
C/EBPβ we set out to investigate the phosphorylation
sites in C/EBPβ that are targeted by p38α and p38β.
Plasmids encoding C/EBPβ (LAP fused with the FLAG
tag) and constitutively active p38α or p38β (fused to
HA) were co-transfected into HEK293T cells. At 48 h
expression of the transfected plasmids was verified by
western blot analysis of HA (p38 MAKPs) and FLAG
(LAP) in the cell lysate. Activation of p38 substrate
ATF2 (via phosphorylation) by expressed p38 MAPKs
was also evaluated by western blot analysis (Figure 1A).
Overexpressed C/EBPβ was pulled down with FLAG-M2
magnetic beads and separated with SDS-PAGE (Figure 1B).
The C/EBPβ band was cut out from the gel and analyzed
by tryptic phosphopeptide mapping utilizing mass spec-
trometry (for original reports see Additional file 1: Table
S1 and Additional file 2: Table S2). Six phosphorylated
amino acid residues were identified in C/EBPβ that was
co-expressed with active p38α and eight phosphorylated
amino acid residues were identified in C/EBPβ that was
co-expressed with active p38β. The two p38 MAPKr-188 and upregulation of atrogin1/MAFbx. C2C12 myoblasts were
with LCM or control medium. In 1 h, levels of p38α and p38β, and
8 h, levels of atrogin1/MAFbx were evaluated by western blotting (B).
atrogin1/MAFbx was analyzed by ANOVA. *denotes a difference from
M treatment (P <0.05). LCM, Lewis lung carcinoma cell-conditioned medium.
Figure 4 p38β specifically activates C/EBPβ-binding to the
atrogin1/MAFbx promoter. (A) C2C12 myoblasts were transfected
with a plasmid encoding constitutively active p38α, p38β or the
empty vector (control). After differentiation, ChIP assay was carried
out to evaluate C/EBPβ binding in myotubes to a 190-base pair
fragment of the atrogin1/MAFbx promoter that contains the
previously identified C/EBPβ-responsive cis-enhancer element [17]
using control and the target PCR primers. Pre-immune IgG used as
the control to the antibody against C/EBPβ did not pull down the
target fragment (data not shown). (B) C2C12 myoblasts were
transfected with siRNA as indicated. After differentiation, myotubes
were treated with LCM or control medium for 1 h and ChIP assay
was carried out to evaluate C/EBPβ binding to the atrogin1/MAFbx
promoter. ChIP, chromosome immunoprecipitation; LCM, Lewis lung
carcinoma cell-conditioned medium.
Figure 5 C/EBPβ phosphorylation at Thr-188 is crucial for atrogin1/M
transfected with a plasmid encoding constitutively active p38α, p38β or em
which Thr-188 was replaced with alanine (LAP-T188A) or the control vecto
lysed and analyzed by western blotting for the expression of LAP-T188A (w
(B) C2C12 myoblasts were transfected with LAP-T188A or the empty vecto
control medium for 8 h. Lysate of myotubes was analyzed by western blot
and C/EBPβ) and atrogin1/MAFbx. Optical density of the bands that repres
from control without LCM treatment and †denotes a difference from contr
cell-conditioned medium.
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(Ser-64, Ser-184, Ser-222, and Ser-276). On the other
hand, p38α uniquely phosphorylated Ser-110 and Tyr-108,
while p38β uniquely phosphorylated Ser-182, Ser-183,
Ser-190 and Thr-188 (Table 1). Among the unique amino
acid residues phosphorylated by p38β, Thr-188 is known
to be crucial for the activation of C/EBPβ binding to its
targeted DNA sequence [31-33].
To verify whether p38β specifically mediates the phos-
phorylation of Thr-188 of C/EBPβ in muscle cells, we
transfected C2C12 myoblasts with plasmids encoding
active p38α or active p38β and used empty vector as the
control. Although constitutively active p38α appeared to
accelerate differentiation during the early stage of differ-
entiation, at 96 h of differentiation, there was no visible
difference in the myotubes formed compared with con-
trol myotubes and active p38β-expressing myotubes.
After differentiation, lysate of myotubes was evaluated
by western blot analysis of expression of the HA tag
that fused to active p38α or p38β, ATF2 activation and
C/EBPβ phosphorylation at Thr-188. As shown in Figure 2,
although both of the active p38 isoforms activated ATF2,
only the expression of active p38β resulted in C/EBPβ
phosphorylation at Thr-188 and upregulation of atrogin1/
MAFbx. Therefore, the specific phosphorylation of
Thr-188 by p38β may be the key to its specific activation
of C/EBPβ.AFbx upregulation by p38β or LCM. (A) C2C12 myoblasts were
pty vector. A plasmid encoding FLAG-tagged C/EBPβ mutant in
r was co-transfected as indicated. After differentiation, myotubes were
ith antibodies against FLAG and C/EBPβ) and atrogin1/MAFbx.
r as control. After differentiation, myotubes were treated with LCM or
ting for the expression of LAP-T188A (with antibodies against FLAG
ent atrogin1/MAFbx was analyzed by ANOVA. *denotes a difference
ol with LCM treatment (P <0.05). LCM, Lewis lung carcinoma
Figure 6 Expression of constitutively active p38β in mouse
muscle induces C/EBPβ phosphorylation at Thr-188. Plasmids
encoding constitutively active p38α or p38β were transfected into
TA of the right leg of wild type or C/EBPβ−/− mice, and the empty
vector into the left leg. In 14 days TA samples were collected,
weighed and lysed. Expression of the p38 isoforms was verified by
western blot analysis of HA tag expression and ATF2 activation. A
representative blot is shown (A). The TA lysate was subjected to
western blot analysis of C/EBPβ phosphorylation at Thr-188 and
FoxO1/3 activation. Representative blots and densitometry data are
shown. Optical density of the bands that represent various proteins
was measured. Levels of protein phosphorylation were normalized
to that of total proteins. *denotes a difference (P <0.05) based on
Student t test (B). TA, tibialis anterior.
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C/EBPβ binding to the atrogin1/MAFbx promoter and
upregulates atrogin1/MAFbx in C2C12 myotubes
To verify whether p38β is critical to Thr-188 phosphoryl-
ation and atrogin1/MAFbx upregulation induced by ca-
chectic tumor cells, siRNA-mediated mRNA knockdown
was carried out. We observed that knockdown of the p38β
expression, but not the p38α expression, blocked Lewis
lung carcinoma cell-conditioned medium (LCM)-induced
Thr-188 phosphorylation (Figure 3A) and atrogin1/MAFbx
upregulation (Figure 3B). Therefore, p38β is indeed a key
mediator of Thr-188 phosphorylation and atrogin1/MAFbx
upregulation by Lewis lung carcinoma.Previously, we observed that MAPK kinase 6 (MKK6)
activates C/EBPβ binding to the C/EBPβ-responsive en-
hancer in the atrogin1/MAFbx promoter via the activa-
tion of p38 [17]. To investigate whether p38β specifically
activates C/EBPβ binding to this C/EBPβ-responsive en-
hancer, we conducted the ChIP assay. We observed in
C2C12 myotubes that the expression of active p38β,
but not active p38α, activated C/EBPβ binding to the
atrogin1/MAFbx promoter region containing the C/EBPβ-
responsive enhancer (Figure 4A). Conversely, siRNA-
mediated knockdown of the p38β gene, but not the p38α
gene, blocked LCM-induced activation of C/EBPβ binding
to the atrogin1/MAFbx promoter (Figure 4B). Thus, we
conclude that p38β specifically activates C/EBPβ binding
to its targeted DNA motif.
To evaluate whether C/EBPβ phosphorylation at Thr-
188 is critical to p38β-mediated upregulation of atrogin1/
MAFbx, a plasmid encoding a C/EBPβ mutant in which
Thr-188 was replaced by alanine (C/EBPβ-T188A) was
transfected into C2C12 myoblasts along with a plasmid
encoding active p38α or active p38β. After differentiation,
levels of atrogin1/MAFbx in myotubes that expressed
active p38β, but not active p38α, were elevated. The
elevation of atrogin1/MAFbx was blocked in myotubes
co-expressing the C/EBPβ-T188A mutant (Figure 5A).
To evaluate whether tumor-induced atrogin1/MAFbx
upregulation requires the phosphorylation of C/EBPβ at
Thr-188, the plasmid encoding C/EBPβ-T188A was
transfected into C2C12 myoblasts. After differentiation,
myotubes were treated with LLC cell-conditioned
medium (LCM). We observed that LCM upregulation of
atrogin1/MAFbx was inhibited in myotubes that overex-
press the C/EBPβ-T188A mutant (Figure 5B). Therefore,
p38β-mediated C/EBPβ phosphorylation at Thr-188 is
crucial for atrogin1/MAFbx upregulation by LLC cells.
p38β MAPK specifically induces atrogin1/MAFbx
upregulation and muscle mass loss in mice via C/EBPβ
We previously showed that C/EBPβ is essential for the
atrogin1/MAFbx upregulation and muscle mass loss in
Lewis lung carcinoma (LLC)-tumor bearing mice [17].
To evaluate whether activation of p38β in vivo specif-
ically induces C/EBPβ phosphorylation at Thr-188,
atrogin1/MAFbx upregulation and muscle mass loss,
the plasmids encoding constitutively active p38α or
p38β were transfected into the tibialis anterior (TA) of
wild type or C/EBPβ−/− mice with the empty vector as
control. At 14 days, the mice were sacrificed and the
excised TAs were analyzed. Expression of the HA tag
that fused to p38α or p38β and activation of the p38
substrate ATF2 were evaluated by western blot analysis
to confirm the expression of active p38α and p38β
(Figure 6A). Expression of active p38β, but not active
p38α, resulted in phosphorylation of C/EBPβ at Thr-
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moter also contains FoxO1/3-responsive cis-elements
that are regulated by AKT [21], we evaluated whether
p38β affected FoxO1/3 activity. Expression of active
p38β did not alter the phosphorylation state of FoxO1/
3 (Figure 6B). Therefore, p38β does not affect FoxO1/
3 activity. As shown in Figure 7A, expression of active
p38β resulted in atrogin1/MAFbx upregulation in the
TA of wild type mice. However, active p38β failed to
upregulate atrogin1/MAFbx in C/EBPβ−/− mice. Finally,
expression of active p38β, but not active p38α, induced
TA weight loss by 14% in wild type mice. In contrast,
active p38β expression did not alter TA weight in C/
EBPβ−/− mice (Figure 7B). Therefore, in vivo activation
of p38β induces atrogin1/MAFbx upregulation and
muscle mass loss via the activation of C/EBPβ.
Discussion
The selective activation of substrates by various p38
MAPK isoforms was previously attributed to preferential
activation of the isoforms by specific MAPK kinase as well
as compartmentalization of the isoforms. For example,
while p38α is activated by MKK3, MKK6 and MKK4,
p38β is activated by MKK6 [10,35]. However, these may
not explain the specific activation of C/EBPβ by p38β, be-
cause both p38α and p38β are present in the nucleus and
activated by MKK6. The current study demonstrates that
the selective activation of substrates by p38 MAPK iso-
forms is further realized by their recognition of specific
phosphorylation sites within a substrate.
Particularly, we show that p38β specifically mediates
the phosphorylation of C/EBPβ required for the activa-
tion of its binding to the atrogin1/MAFbx promoter.
Previous studies indicated that phosphorylation of Thr-Figure 7 Expression of constitutively active p38β in mouse muscle in
C/EBPβ-dependent manner. The TA lysate derived from Figure 6 was furt
Representative blots and densitometry data are shown (A). The weight of T
compared to that of TA transfected with empty vector (control) from the s
tibialis anterior.188 in C/EBPβ by ERK1/2 MAPK [31] or cdk2/cyclinA
[32] primes C/EBPβ for subsequent phosphorylation on
Ser-184 or Thr-179 by glycogen synthase kinase 3β
(GSK3β), which activates the DNA-binding and transacti-
vation functions of C/EBPβ [33]. Our data presented here
demonstrate that p38β has the unique capability of medi-
ating dual phosphorylation at both Thr-188 and Ser-184,
resulting in the activation of C/EBPβ binding to the atro-
gin1/MAFbx promoter. In contrast, p38α that mediates
phosphorylation of Ser-184 but not Thr-188 is unable to
activate C/EBPβ binding to the atrogin1/MAFbx pro-
moter. Because GSK3β was previously shown inactivated
by p38 MAPK-mediated phosphorylation [36], it is un-
likely that GSK3β mediates C/EBPβ phosphorylation at
Ser-184 in response to p38α and p38β activation.
In the present study we also present the first evidence
that overexpression of active p38β in muscle induces
muscle catabolism, demonstrating a direct effect of p38β
on muscle catabolism in vivo. Previous studies involving
systemic activation of p38 in tumor-bearing mice [17] or
septic mice [4] did not allow such a conclusion.
Although p38β is widely distributed in various tissues
[37] its function is largely unknown, especially when it is
compared to p38α, which is not only responsible for the
known roles of p38 in inflammatory responses [38,39]
but also in the regulation of myogenesis [12,13]. The
present study demonstrates that activation of p38β, not
p38α, induces atrogin1/MAFbx upregulation and muscle
mass loss via specific phosphorylation of C/EBPβ, which
explains at the molecular level why p38 is capable of
playing the seemingly opposing roles in muscle protein
homeostasis (promoting myogenesis versus promoting
muscle catabolism). Further, these data support p38β
as a selective therapeutic target of cachexia. Becauseduces atrogin1/MAFbx upregulation and muscle mass loss in a
her analyzed for level of atrogin1/MAFbx by western blotting.
A transfected with a plasmid encoding an active p38 isoform was
ame mouse (B). *denotes a difference (P <0.05) based on ANOVA. TA,
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lates a wide variety of genes [40], it may not be suit-
able as a drug target. On the other hand, p38β has few
known functions, therefore, specific inhibitors of p38β
MAPK would be highly desirable for the intervention
of cancer cachexia. Unfortunately, only p38α/β-dual or
p38α-specific inhibitors are available at the present time.
Because p38β is highly expressed in the heart [37], it
may also regulate the protein homeostasis in heart
muscle via influencing C/EBPβ−regulated atrogin1/
MAFbx expression. Consistent to this notion, it has been
shown recently that exercise induces a reduction in C/
EBPβ in cardiomyocytes, which mediates cardiomyocyte
hypertrophy [41]. In addition, the transactivation activity
of C/EBPβ is suppressed by insulin, an anabolic hor-
mone [42]. Therefore, diverse signaling pathways that
regulate protein homeostasis in striated muscles may
converge upon C/EBPβ.
Conclusions
The present study demonstrates that the α and β isoforms
of p38 MAPK recognize distinct phosphorylation sites in
a substrate. p38β MAPK has the unique capacity to medi-
ate the dual phosphorylation of Thr-188 and Ser-184 in
C/EBPβ, thereby, activating this transcription factor and
inducing muscle catabolism. Therefore, p38β MAPK
should be considered as a therapeutic target for cachexia.
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